These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Deletion of a tripeptide sequence from the growth-factor domain of tissue-type plasminogen activator prolongs in vivo circulation. Browne MJ; Chapman CG; Dodd I; Esmail AF; Robinson JH Thromb Res; 1990 Aug; 59(3):687-92. PubMed ID: 2122547 [No Abstract] [Full Text] [Related]
3. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Larsen GR; Metzger M; Henson K; Blue Y; Horgan P Blood; 1989 May; 73(7):1842-50. PubMed ID: 2496774 [TBL] [Abstract][Full Text] [Related]
4. Studies on the effect of fucosylated and non-fucosylated finger/growth-factor constructs on the clearance of tissue-type plasminogen activator mediated by the low-density-lipoprotein-receptor-related protein. Camani C; Gavin O; Bertossa C; Samatani E; Kruithof EK Eur J Biochem; 1998 Feb; 251(3):804-11. PubMed ID: 9490055 [TBL] [Abstract][Full Text] [Related]
5. Fibrin affinity and clearance of t-PA deletion and substitution analogues. Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048 [TBL] [Abstract][Full Text] [Related]
6. Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site. Dodd I; Nunn B; Robinson JH Thromb Haemost; 1988 Jun; 59(3):523-8. PubMed ID: 3142086 [TBL] [Abstract][Full Text] [Related]
7. A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain. Browne MJ; Carey JE; Chapman CG; Tyrrell AW; Entwisle C; Lawrence GM; Reavy B; Dodd I; Esmail A; Robinson JH J Biol Chem; 1988 Feb; 263(4):1599-602. PubMed ID: 2828346 [TBL] [Abstract][Full Text] [Related]
8. Comparison of drug disposition between wild-type and novel tissue-type plasminogen activator pamiteplase in rats. Oikawa K; Watanabe T; Higuchi S Drug Metab Dispos; 2000 Sep; 28(9):1087-93. PubMed ID: 10950854 [TBL] [Abstract][Full Text] [Related]
9. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor- and kringle 1-domains. Emeis JJ; Verheijen JH Ann N Y Acad Sci; 1992 Dec; 667():421-3. PubMed ID: 1309064 [No Abstract] [Full Text] [Related]
11. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration. Lucore CL; Fujii S; Sobel BE Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004 [TBL] [Abstract][Full Text] [Related]
12. Total body and hepatic clearance in rats of recombinant tissue-type plasminogen activator expressed in mouse C127 and Chinese hamster ovary cells. Hori R; He YL; Shima T; Inui K; Aoki S; Okumura K; Tanigawara Y Drug Metab Dispos; 1992; 20(4):541-6. PubMed ID: 1356732 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics in chimpanzees of recombinant human tissue-type plasminogen activator produced in mouse C127 and Chinese hamster ovary cells. Tanigawara Y; Hori R; Okumura K; Tsuji J; Shimizu N; Noma S; Suzuki J; Livingston DJ; Richards SM; Keyes LD Chem Pharm Bull (Tokyo); 1990 Feb; 38(2):517-22. PubMed ID: 2110870 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. Martin U; von Möllendorff E; Akpan W; Kientsch-Engel R; Kaufmann B; Neugebauer G Thromb Haemost; 1991 Nov; 66(5):569-74. PubMed ID: 1725068 [TBL] [Abstract][Full Text] [Related]
15. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains. Emeis JJ; Verheijen JH Arzneimittelforschung; 1992 Mar; 42(3):358-62. PubMed ID: 1497699 [TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361 [TBL] [Abstract][Full Text] [Related]
17. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Hotchkiss A; Refino CJ; Leonard CK; O'Connor JV; Crowley C; McCabe J; Tate K; Nakamura G; Powers D; Levinson A Thromb Haemost; 1988 Oct; 60(2):255-61. PubMed ID: 2851193 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of tissue-type plasminogen activator (tPA) clearance by the liver. Otter M; Kuiper J; van Berkel TJ; Rijken DC Ann N Y Acad Sci; 1992 Dec; 667():431-42. PubMed ID: 1339243 [No Abstract] [Full Text] [Related]
19. 39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. Warshawsky I; Bu G; Schwartz AL J Clin Invest; 1993 Aug; 92(2):937-44. PubMed ID: 8349826 [TBL] [Abstract][Full Text] [Related]
20. Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins. van Zonneveld AJ; Veerman H; Brakenhoff JP; Aarden LA; Cajot JF; Pannekoek H Thromb Haemost; 1987 Feb; 57(1):82-6. PubMed ID: 2438798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]